Equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) will report earnings per share of ($0.63) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Kiniksa Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.64). Kiniksa Pharmaceuticals posted earnings of ($0.66) per share during the same quarter last year, which would indicate a positive year over year growth rate of 4.5%. The business is scheduled to announce its next earnings report on Thursday, November 4th.
On average, analysts expect that Kiniksa Pharmaceuticals will report full-year earnings of ($2.57) per share for the current financial year, with EPS estimates ranging from ($2.60) to ($2.51). For the next year, analysts forecast that the firm will post earnings of ($1.96) per share, with EPS estimates ranging from ($2.10) to ($1.74). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, August 3rd. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.08. The firm had revenue of $7.70 million during the quarter, compared to the consensus estimate of $2.56 million.
Several hedge funds and other institutional investors have recently modified their holdings of KNSA. SG Americas Securities LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the first quarter valued at $105,000. Royal Bank of Canada increased its stake in shares of Kiniksa Pharmaceuticals by 180.7% in the first quarter. Royal Bank of Canada now owns 5,701 shares of the company’s stock valued at $105,000 after buying an additional 3,670 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals in the second quarter valued at $153,000. JPMorgan Chase & Co. increased its stake in shares of Kiniksa Pharmaceuticals by 26.6% in the second quarter. JPMorgan Chase & Co. now owns 12,756 shares of the company’s stock valued at $178,000 after buying an additional 2,683 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Kiniksa Pharmaceuticals in the second quarter valued at $184,000. 42.07% of the stock is owned by institutional investors.
KNSA stock traded up $0.19 during midday trading on Wednesday, hitting $11.67. The stock had a trading volume of 161,138 shares, compared to its average volume of 451,815. The firm has a market capitalization of $799.66 million, a price-to-earnings ratio of -4.20 and a beta of -0.02. Kiniksa Pharmaceuticals has a 52 week low of $10.65 and a 52 week high of $24.70. The stock has a 50-day simple moving average of $12.12 and a 200 day simple moving average of $14.02.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404.
Featured Story: Dual Listing What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.